Tirzapetide dose escalation schedules were slower in the real-world than clinical settings among individuals with obesity without T2D.

In light of President Donald Trump’s impending pharma tariffs, several big companies have made massive manufacturing ...

Just four months after Eli Lilly and British biotech Alchemab penned a discovery collaboration, the Big Pharma is licensing ...

Financial terms of the new agreement include an upfront payment to secure rights to Alchemab's lead ALS candidate, ATLX-1282, ...

U.K.-based biotech Alchemab on Tuesday announced a licensing agreement with Eli Lilly (NYSE:LLY) to jointly develop ATLX-1282 ...

Lilly plans to break ground Tuesday afternoon on its $4.5 billion Lilly Medicine Foundry in Lebanon. Lilly Chair and CEO Dave ...

LLY is bullish in weekly sequence from all time low. It favors rally in (V) after double correction ended at $677.09 low in ...

U.S. stock index futures were lower on Tuesday after President Donald Trump's comments on potential pharma tariffs renewed ...

DoorDash was down 5% after the meal delivery firm said it would buy Deliveroo in a deal valuing the British rival at about ...

Baron Fifth Avenue Growth Fund declined during the first quarter of 2025, underperforming its benchmark, the Russell 1000 ...

Research and development (R&D) investment in the Swiss biotech sector grew in 2024, despite ongoing global funding struggles.